Evidence map›Paper›PMID 38392922›Full record

ArticlePharmacy (Basel, Switzerland)2023

Cancer-Chemotherapy-Related Regimen Checks Performed by Pharmacists of General Hospitals Other than Cancer Treatment Collaborative Base Hospitals: A Multicenter, Prospective Survey.

Daisuke Ueki, Shinya Suzuki, Takahiro Ohta, Akira Shinohara, Yasukata Ohashi, Daisuke Konuma, Yasuaki Ryushima, Ryoko Udagawa, Hironori Motoshige, Masahiro Ieoka and 7 more

Abstract read
In one paragraph

Article in Pharmacy (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Daisuke UekiDepartment of Pharmacy, National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan.
Shinya SuzukiDepartment of Pharmacy, National Cancer Center Hospital East, Chiba 277-8577, Japan.ORCID 0000-0002-2134-887X
Takahiro OhtaDepartment of Pharmacy, National Hospital Organization Tokyo Medical Center, Tokyo 152-8902, Japan.
Akira ShinoharaDepartment of Pharmacy, National Cancer Center Hospital East, Chiba 277-8577, Japan.
Yasukata OhashiDepartment of Pharmacy, National Center for Global Health and Medicine, Tokyo 162-8655, Japan.
Daisuke KonumaDepartment of Pharmacy, National Hospital Organization Chiba Medical Center, Chiba 260-8606, Japan.
Yasuaki RyushimaDepartment of Pharmacy, National Hospital Organization Saitama Hospital, Saitama 351-0102, Japan.
Ryoko UdagawaDepartment of Pharmacy, National Cancer Center Hospital, Tokyo 104-0045, Japan.
Hironori MotoshigeDepartment of Pharmacy, National Hospital Organization Hokkaido Medical Center, 5-7 Yamanote, Nishi-ku, Sapporo 063-0005, Japan.
Masahiro IeokaDepartment of Pharmacy, National Hospital Organization Hamada Medical Center, Matsue 697-8511, Japan.
Akihiro TajiDepartment of Pharmacy, National Hospital Organization Osaka Minami Medical Center, Osaka 586-8521, Japan.
Yuuki KogureDepartment of Pharmacy, National Hospital Organization Higashihiroshima Medical Center, Hiroshima 739-0041, Japan.
Mikako HiraikeDepartment of Pharmacy, National Hospital Organization Kumamoto Medical Center, Kumamoto 860-0008, Japan.
Miyuki UoiDepartment of Pharmacy, National Hospital Organization Kyusyu Cancer Center, Fukuoka 811-1395, Japan.
Kazuhiko InoDepartment of Pharmacy, National Hospital Organization Tokyo National Hospital, Tokyo 204-8585, Japan.
Toshikatsu KawasakiDepartment of Pharmacy, National Cancer Center Hospital East, Chiba 277-8577, Japan.
Masakazu YamaguchiDepartment of Pharmacy, Cancer Institute Hospital, Tokyo 135-8550, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although prescription review is an important role for pharmacists in anticancer drug therapy, there are no guidelines in Japan that specify what pharmacists should check for in chemotherapy regimens. This prospective multicenter survey aimed to investigate the implementation of chemotherapy regimen checks by pharmacists in general hospitals by focusing on 19 recommended confirmation items designed to enhance chemotherapy safety. This study involved 14 hospitals within the National Hospital Organization in different regions of Japan. The top five cancers in Japan (gastric, colorectal, lung, breast, and gynecological) were targeted and specific chemotherapy regimens were analyzed. This study assessed the amount of time required for regimen checks, the number of confirmation items completed, the number and the content of inquiries raised regarding prescriptions, and the pharmacists' opinions using a questionnaire that had a maximum score of 10 points. Pharmacists checked 345 and 375 chemotherapies of patients in the control group (CG) and recommended items group (RIG), respectively. The mean time periods required for completing a chemotherapy regimen check were 4 min and 14 s (SD ±1 min and 50 s) and 6 min and 18 s (SD, ±1 min and 7 s) in the CG and RIG, respectively. The mean of the recommended items for the CG = 12.4 and for the RIG = 18.6. The items that the pharmacists did not confirm included urine protein (sixty-nine cases, 18.4%), allergy history (four cases, 1%), previous history (two cases, 0.5%), and a previous history of hepatitis B virus (sixty-nine cases, 18.4%). The number of inquiries for a doctor's prescription order was higher in the RIG than in the CG (41 vs. 27 cases). This multicenter survey demonstrated the potential effectiveness of implementing 19 recommended confirmation items in the regimen checks by pharmacists in general hospitals other than cancer treatment collaborative base hospitals.

Indexed as

cancer chemotherapychemotherapy regimen checkshospital pharmacistpharmacist intervention

Identifiers

PMID38392922
PMCPMC10891652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.